Top-Rated StocksTop-RatedPositive News SentimentPositive NewsNASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free GH Stock Alerts $30.50 +0.29 (+0.96%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$29.75▼$30.8850-Day Range$16.07▼$31.8452-Week Range$15.81▼$41.06Volume1.97 million shsAverage Volume2.08 million shsMarket Capitalization$3.73 billionP/E RatioN/ADividend YieldN/APrice Target$36.91 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Guardant Health alerts: Email Address Guardant Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside21.0% Upside$36.91 Price TargetShort InterestHealthy6.78% of Shares Sold ShortDividend StrengthN/ASustainability-0.51Upright™ Environmental ScoreNews Sentiment1.57Based on 4 Articles This WeekInsider TradingAcquiring Shares$38,972 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.31) to ($3.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.46 out of 5 starsMedical Sector96th out of 913 stocksMedical Laboratories Industry4th out of 20 stocks 3.4 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGuardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardant Health's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.78% of the outstanding shares of Guardant Health have been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guardant Health has recently decreased by 22.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 71.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.51. Previous Next 2.5 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Guardant Health this week, compared to 4 articles on an average week.Search InterestOnly 26 people have searched for GH on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have bought 1,298.35% more of their company's stock than they have sold. Specifically, they have bought $38,972.00 in company stock and sold $2,787.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Guardant Health's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($3.31) to ($3.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -7.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -7.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 22.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Guardant Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> About Guardant Health Stock (NASDAQ:GH)Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Read More GH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GH Stock News HeadlinesJune 6, 2024 | seekingalpha.comGuardant: Double-Digit Sales Projections Come At A CostMay 31, 2024 | businesswire.comGuardant Health Named to TIME100 Most Influential CompaniesMay 30, 2024 | businesswire.comGuardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer ScreeningMay 25, 2024 | bizjournals.comPeninsula cancer test maker lands key nod from FDA panel, a step toward a big paydayMay 24, 2024 | markets.businessinsider.comEvaluating Guardant Health: Insights From 5 Financial AnalystsMay 24, 2024 | za.investing.comExact Sciences stock drops as Guardant Health test supported by FDA panelMay 24, 2024 | msn.comFDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer ScreeningMay 24, 2024 | msn.comGuardant jumps as trading resumes after FDA AdCom vote on cancer testMay 24, 2024 | finance.yahoo.comGuardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood TestsMay 24, 2024 | investors.comGuardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer TestMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Guardant Health Amid Positive FDA Outlook and Market OpportunityMay 23, 2024 | businesswire.comFDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening OptionMay 23, 2024 | reuters.comU.S. FDA advisers back approval for Guardant's blood-based cancer testMay 23, 2024 | finance.yahoo.comNatera to Present at the 2024 Leerink Partners Healthcare Crossroads ConferenceMay 23, 2024 | markets.businessinsider.comGuardant Health Trading Suspended On Nasdaq Pending ShieldTM's Premarket Approval MeetingMay 23, 2024 | msn.comGuardant shares on hold for trading ahead of AdCom meeting on cancer testMay 23, 2024 | businesswire.comGuardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer ScreeningMay 22, 2024 | businesswire.comGuardant Health to Participate in Upcoming Investor ConferencesMay 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: TELA Bio (TELA), Rezolute (RZLT)May 21, 2024 | reuters.comUS FDA staff says Guardant's cancer test may fail to detect some tumorsMay 21, 2024 | msn.comGuardant Health slips as FDA comments on cancer screening testMay 21, 2024 | businesswire.comTrinity Industries, Inc. Announces Offering of Additional 7.750% Senior Notes Due 2028May 21, 2024 | businesswire.comGuardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic IndicationsMay 17, 2024 | businesswire.comGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | businesswire.comGuardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease WeekSee More Headlines Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/18/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,779Year FoundedN/APrice Target and Rating Average Stock Price Target$36.91 High Stock Price Target$50.00 Low Stock Price Target$27.00 Potential Upside/Downside+21.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-479,450,000.00 Net Margins-76.34% Pretax Margin-76.20% Return on Equity-246.47% Return on Assets-25.86% Debt Debt-to-Equity Ratio16.70 Current Ratio5.95 Quick Ratio5.66 Sales & Book Value Annual Sales$563.95 million Price / Sales6.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book22.76Miscellaneous Outstanding Shares122,370,000Free Float115,639,000Market Cap$3.73 billion OptionableNot Optionable Beta1.14 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Helmy Eltoukhy Ph.D. (Age 44)Co-Founder, Co-CEO & Chairman Comp: $11.63kDr. AmirAli Talasaz Ph.D. (Age 44)Co-CEO & Director Comp: $11.18kMr. Michael Bell (Age 55)Chief Financial Officer Comp: $630.99kMr. John G. Saia (Age 51)Chief Legal Officer & Corporate Secretary Comp: $627.18kDr. Craig Eagle M.D. (Age 57)Chief Medical Officer Comp: $649.13kMr. Christopher Freeman (Age 50)Chief Commercial Officer Comp: $630.39kMs. Darya ChudovaChief Technology OfficerMr. Kumud Kalia (Age 58)Chief Information Officer Ms. Jennifer HigginsVice President of Public AffairsMs. Terilyn Juarez Monroe (Age 57)Chief People Officer More ExecutivesKey CompetitorsGenetronNASDAQ:GTHQiagenNYSE:QGENNateraNASDAQ:NTRAExact SciencesNASDAQ:EXASRadNetNASDAQ:RDNTView All CompetitorsInsiders & InstitutionsMeghan V JoyceSold 100 sharesTotal: $2,787.00 ($27.87/share)Teachers Retirement System of The State of KentuckyBought 10,000 shares on 5/28/2024Ownership: 0.125%Beck Bode LLCBought 60,851 shares on 5/22/2024Ownership: 0.166%Adalta Capital Management LLCBought 9,565 shares on 5/17/2024Ownership: 0.058%Comerica BankSold 9,109 shares on 5/17/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions GH Stock Analysis - Frequently Asked Questions Should I buy or sell Guardant Health stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GH shares. View GH analyst ratings or view top-rated stocks. What is Guardant Health's stock price target for 2024? 14 equities research analysts have issued 1-year price targets for Guardant Health's shares. Their GH share price targets range from $27.00 to $50.00. On average, they predict the company's share price to reach $36.91 in the next year. This suggests a possible upside of 21.0% from the stock's current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts. How have GH shares performed in 2024? Guardant Health's stock was trading at $27.05 at the beginning of 2024. Since then, GH shares have increased by 12.8% and is now trading at $30.50. View the best growth stocks for 2024 here. Are investors shorting Guardant Health? Guardant Health saw a decline in short interest in May. As of May 31st, there was short interest totaling 8,300,000 shares, a decline of 22.9% from the May 15th total of 10,760,000 shares. Based on an average daily trading volume, of 2,350,000 shares, the days-to-cover ratio is presently 3.5 days. View Guardant Health's Short Interest. When is Guardant Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GH earnings forecast. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.94). The business had revenue of $168.49 million for the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative net margin of 76.34% and a negative trailing twelve-month return on equity of 246.47%. What ETFs hold Guardant Health's stock? ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Tema Oncology ETF (CANC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Genomic Revolution ETF (ARKG), BNY Mellon Innovators ETF (BKIV), Fidelity Disruptive Medicine ETF (FMED) and iShares U.S. Healthcare Providers ETF (IHF). What guidance has Guardant Health issued on next quarter's earnings? Guardant Health issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $675.0 million-$685.0 million, compared to the consensus revenue estimate of $664.0 million. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO). When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Guardant Health's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.40%), Baillie Gifford & Co. (5.12%), Capital International Investors (3.12%), Price T Rowe Associates Inc. MD (1.26%), Jennison Associates LLC (0.40%) and Mitsubishi UFJ Trust & Banking Corp (0.33%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Meghan V Joyce, Stanley J Meresman and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GH) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardant Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.